fashion -WSS

fashion

author：entertainment 2025-09-27 10:00:15 - browse：34531

Yichuan Cao/Sipa USA via AP Images

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed.

The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike.

Drugs like Trodelvy, known as antibody drug conjugates, are one of the hottest areas in oncology. The idea is that these medicines combine an antibody, which is triggered when it binds to a protein on a cancer cell, with a “payload” of chemotherapy that poisons the cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Fauci’s Covid grilling leads GOP to weigh foreign research rules

WSS

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Update the Apgar Score to remove skin color

Flu vaccine reformulation won't be easy, manufacturers warn

As JPM 2024 winds down, some health tech firms project optimism

New England Journal of Medicine addresses racist history, slavery

FDA endorses new sterilization method for medical devices

explore

fashion

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

There's an unseen cost to disruptive road

Novavax promises a turnaround & Lilly roils the obesity market

Dog Aging Project founders on what lies ahead after losing funding

Walensky prepares to leave CDC — and Congress — behind

Head of FDA's diagnostics center, who led through Covid, retires

Trump demands the U.S. pay no more for drugs than other countries … again

Printout prescription drug information shouldn’t go digital

Walensky prepares to leave CDC — and Congress — behind

Microsoft launches AI tool for clinical documentation through Epic

explore

HPV vaccine, cervical cancer study delivers historic results

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Cardiologists urge adding sexual orientation, gender identity to health records

New menopause drug shows promise in relief for hot flashes

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

JPM 2024: Nvidia claims we're in biological revolution. Are we?

hotspot

explore

entertainment

focus